Aveta Biomics has developed multiple assets with worldwide rights. We expect these assets to treat other cancers with common underlying disease biology.
Oral Squamous Cell Carcinoma
Recurrent High-grade Glioma
The worldwide incidence of OSCC is over 500,000 with a five year mortality rate of about 50% which has remained unchanged for decades. Highly molecularly heterogeneous tumor poses serious challenges for targeted approaches. The recurrence rates exceed 30%. APG-157, through a multi-targeted mechanism, kills active tumor through selective apoptosis and simultaneously stimulating the immune system. It further aims to prevent recurrence through the arrest of cancer stem cells. It is the first drug of its kind that is administered orally and thus has topical application as well as systemic absorption through the oral cavity.
High-grade gliomas include glioblastoma, gliosarcoma, H3K27M mutant glioma, anaplastic astrocytoma, and anaplastic oligodendroglioma. About 80% of the patients get Bevacizumab monotherapy with poor outcomes. APG-157, working through a novel mechanism, is expected to overcome the resistance mechanisms for Bevacizumab and also potentially complement tumor killing by additional mechanisms including microglia reprogramming from M2 to tumoricidal M1 state. This study opens up expansion opportunities to combine APG-157 with Bevacizumab for other cancers
Glioblastoma is one of the brain cancers with a median survival of 12 to 14 months and represents a huge unmet need. Annual US incidence is over 13,000 patients. Molecular characteristics of this cancer present unique challenges. AMAX-126 works through a completely novel, multi-targeted mechanism. It is administered orally.